Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:42:50.347Z.
Calculation as of: 2026-10-06T19:42:50.347Z.
Quote observation: 2026-10-06T19:26:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c2871aed35905ca893ff96a4b2ab646902ae69530b401aedab5470ff00d0a486
PE RATIO
N/A
Optimi Health Corp.
Market Cap
$13.48M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| Optimi Health Corp. (OPTH) | $13.48M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.31M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.12M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.85M | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.99M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.11M | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.18M | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.77M | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.63M | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.47M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
